Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

Executive Summary

FDA's decision to withdraw approval of Roche/Genentech's Avastin for first-line metastatic breast cancer is proving to be an unpopular action, though the ramifications are not yet clear.

You may also be interested in...



Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends

EMD Serono had not marketed the infertility treatment in US since 2012, when it first asked FDA to withdraw application; company was unable to complete confirmatory trial required under accelerated approval.

Perjeta, Avastin Breast Cancer Approvals Are A Study In Contrasts

Pertuzumab’s approval came almost a year after FDA and Genentech battled over the future of bevacizumab’s breast cancer claim at an unprecedented public hearing. While both oncologic agents were approved on the basis of a median progression-free survival benefit exceeding five months, the regulatory similarities end there.

Women's Right To Choose Avastin Debated During House PDUFA Hearing

Discussion of the status of Avastin's indication for metastatic breast cancer at a July 7 House hearing can be seen as a surrogate for several debates that could unfold during the user fee reauthorization process – including FDA approval standards, conflict-of-interest screening for advisory committees and pricing.

Related Content

Topics

UsernamePublicRestriction

Register

PS052948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel